Are Kilitch Drugs latest results good or bad?

Kilitch Drugs (India) has reported its financial results for the quarter ending March 2025, showcasing notable growth across several key metrics. The company achieved a Profit Before Tax (PBT) of Rs 12.14 crore, which represents a significant increase compared to the average of the previous four quarters. Profit After Tax (PAT) also saw a substantial rise, reaching Rs 10.40 crore, indicating strong profitability during this period.
Net sales reached Rs 61.23 crore, marking a five-quarter high and reflecting a solid increase from the previous average. The operating profit stood at Rs 14.60 crore, with an operating profit margin of 23.84%, suggesting enhanced operational efficiency. Additionally, earnings per share (EPS) hit Rs 6.47, the highest in five quarters, demonstrating the company’s focus on shareholder value.

However, it is important to note that Kilitch Drugs has faced rising interest costs, which have increased by 47.06% over the last six months. Despite this challenge, the overall financial outlook appears robust, highlighting the company's strong performance in the competitive pharmaceutical sector.

In light of these results, the company saw an adjustment in its evaluation, reflecting the operational trends and financial performance reported. The quarterly results indicate a net sales growth of 9.01% compared to the previous quarter, while the consolidated net profit experienced a notable growth of 74.50%. Overall, Kilitch Drugs has demonstrated a strong operational performance amidst rising interest costs.